Close Menu

NEW YORK (360Dx) – Diagnostic company executives are eagerly anticipating the repeal, which could come as early as this year, of a 2.3 percent excise tax on medical devices established in 2010 as part of the Affordable Care Act.

The tax was levied against all FDA-listed diagnostic tests and devices intended to diagnose a disease or condition and went into effect in 2013; the tax did not apply to OTC products, such as pregnancy tests. It was imposed on device and diagnostic sales between 2013 and 2015 but has been suspended twice since then.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.